Dorman Products reports Q1 results today with options traders positioned more bullishly than at any point in recent months.
The clearest signal is the put/call ratio. It has fallen to 0.55, well below its 20-day average of 0.58, and a dramatic reversal from the 0.97 readings seen in early April when tariff anxiety gripped the auto parts sector. That rotation toward calls reflects growing confidence rather than defensive hedging. The stock has followed the same arc — down sharply in early April, it has recovered 10% over the past month to $110.85, giving back just 1.8% on Monday ahead of the print.
Short interest is a secondary story here rather than the primary one. Shorts hold roughly 4.3% of the free float, a level that has been creeping higher — up about 9% over the past month. But borrowing conditions remain anything but stressed. The cost to borrow runs at just 0.43%, and availability is generous, suggesting no meaningful squeeze pressure in the lending market. The ORTEX short score has drifted between 43 and 45 over the past two weeks, broadly neutral territory. The short side is building incrementally, but it is not an aggressive bet.
The analyst community is largely constructive, though the consensus tells a nuanced story. Targets across active coverage cluster around $150, a roughly 35% premium to Monday's close. Jefferies upgraded to Buy in early March, even while cutting its target to $140, signalling conviction on the direction of travel if not the near-term level. Wells Fargo and Freedom Broker both trimmed targets after the February print, when the stock fell nearly 8% on the day and extended losses to around 8% over the following week. That Q4 reaction sits as a live reference point for bears. Bulls counter that the stock's P/E has expanded to 13.2x — up more than 1.3 turns over the past month — pricing in a recovery narrative that management now needs to validate. The EV/EBITDA multiple at 9.5x remains measured by sector standards, giving the valuation argument some room.
Ownership is tightly held. BlackRock and Vanguard account for roughly 23% of shares between them, while the Berman family — longtime controlling shareholders — together hold close to 11%, though Marc Berman trimmed by 106,000 shares in late March. Executive-level selling was broad in early March, with the CEO, General Counsel, and CIO all selling at prices around $116. That cluster of sales came before the stock pulled back to the low $100s, and the recovery to $110 means insiders who sold then are sitting on decisions that look well-timed.
The print will test whether Dorman's Q1 results support the recovery story that options traders have already started to price in — and whether margins held up well enough to push the stock back toward analyst targets that remain well above current levels.
See the live data behind this article on ORTEX.
Open DORM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
